IL-15 is posited to also effect CAR T by increasing T cell numbers through altered metabolic activity and survival, by enhancing effector function (i.e., breaking tolerance to tumor and activating otherwise tolerant T cells), and by promoting the early trafficking of effector and memory T cells to desired locations for therapeutic effect. The gene discussed is IL15; the disease is neoplasm.